# Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

> **NCT05510219** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Obinutuzumab
- Rapid Infusion
- Intravenous Infusion Reaction

## Interventions

- **DRUG:** intravenous rapid infusion of obinutuzumab

## Key facts

- **NCT ID:** NCT05510219
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05510219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05510219, "Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05510219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*